Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 608

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials

Boissel, Nicolas, Auclerc, Marie-Françoise, Lhéritier, Véronique, Perel, Yves, Thomas, Xavier, Leblanc, Thierry, Rousselot, Philippe, Cayuela, Jean-Michel, Gabert, Jean, Fegueux, Nathalie, Piguet, Christophe, Huguet-Rigal, Françoise, Berthou, Christian, Boiron, Jean-Michel, Pautas, Cécile, Michel, Gérard, Fière, Denis, Leverger, Guy, Dombret, Hervé, Baruchel, André·2003·Journal of Clinical Oncology

Abstract

Purpose: To compare pediatric and adult therapeutic practices in the treatment of acute lymphoblastic leukemia (ALL) in adolescents. Patients and Methods: From June 1993 to September 1994, 77 and 100 adolescents (15 to 20 years of age) were enrolled in the pediatric FRALLE-93 and adult LALA-94 protocols, respectively. Among the different prognostic factors, we retrospectively analyzed the effect of the trial on achieving complete remission (CR) and event-free survival (EFS). Results: Patients were younger in the FRALLE-93 than in the LALA-94 protocol (median age, 15.9 v 17.9 years, respectively), but other characteristics were similar, including median WBC count (18 × 10 9 cells/L v 16 × 10 9 cells/L), B/T-lineage (54 of 23 v 72 of 28 patients), CD10-negative ALL (13% v 15%), and poor-risk cytogenetics (t(9;22), t(4;11), or hypodiploidy less than 45 chromosomes: 6% v 5%). The CR rate depended on WBC count (P = .005) and trial (94% v 83% in FRALLE-93 and LALA-94, respectively; P = .04). Univariate analysis showed that unfavorable prognostic factors for EFS were as follows: the trial (estimated 5-year EFS, 67% v 41% for FRALLE-93 and LALA-94, respectively; P < .0001), an increasing WBC count (P < .0001), poor-risk cytogenetics (P = .005), and T-lineage (P = .01). The trial and WBC count remained significant parameters for EFS in multivariate analysis (P < .0001 and P = .0004). Lineage subgroup analysis showed an advantage for the FRALLE-93 trial for CR achievement (98% v 81%; P = .002) and EFS (P = .0002) in B-lineage ALL and for EFS (P = .05) in T-lineage ALL. Age was not a significant prognostic factor in this population of adolescents. Conclusion: This study’s findings indicate that adolescents should be included in intensive pediatric protocols and that new trials should be designed, inspired by pediatric protocols, for the treatment of young adults with ALL.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2003.02.053

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 608

Metadata

Authors
Boissel, N., Auclerc, M.-F., Lhéritier, V., Perel, Y., Thomas, X., Leblanc, T., Rousselot, P., Cayuela, J.-M., Gabert, J., Fegueux, N., Piguet, C., Huguet-Rigal, F., Berthou, C., Boiron, J.-M., Pautas, C., Michel, G., Fière, D., Leverger, G., Dombret, H., & Baruchel, A.
Venue
Journal of Clinical Oncology
Published
2003-03-01
Volume
21
Issue
5
Pages
774-780
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2146762986
Cited by
608
References
21
FWCI
21.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. https://app.cochat.ai/papers/10.1200/jco.2003.02.053
The paper
Boissel, N., Auclerc, M.-F., Lhéritier, V., Perel, Y., Thomas, X., Leblanc, T., Rousselot, P., Cayuela, J.-M., Gabert, J., Fegueux, N., Piguet, C., Huguet-Rigal, F., Berthou, C., Boiron, J.-M., Pautas, C., Michel, G., Fière, D., Leverger, G., Dombret, H., & Baruchel, A. (2003). Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2003.02.053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.